Sagimet Biosciences Inc expected to post a loss of 51 cents a share - Earnings Preview
12/08/2025 14:14
Sagimet Biosciences Inc SGMT.OQ SGMT.O is expected to show no change in quarterly revenue when it reports results on August 14 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Sagimet Biosciences Inc is for a loss of 51 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Sagimet Biosciences Inc is $27.50, about 68.2% above its last closing price of $8.75 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.63 | -0.67 | -0.56 | Beat | 15.9 |
| Dec. 31 2025 | -0.61 | -0.62 | -0.50 | Beat | 19.5 |
| Sep. 30 2024 | -0.39 | -0.41 | -0.45 | Missed | -10.5 |
| Jun. 30 2024 | -0.33 | -0.33 | -0.25 | Beat | 24.5 |
| Mar. 31 2024 | -0.41 | -0.40 | -0.23 | Beat | 42.1 |
| Dec. 31 2023 | -0.47 | -0.56 | -0.78 | Missed | -40.2 |
| Sep. 30 2023 | -0.99 | -0.99 | -0.35 | Beat | 64.8 |
| Jun. 30 2023 | -0.50 | -0.50 | -35.80 | Missed | -7,096 |
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage